Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 6, 2003, Pages 441-447

  Delorme, Jean ^a   Badin, Stéphanie ^a   Le Corroller, Anne Gaelle G ^a   Auvrignon, Anne Aurtignon ^b   Auclerc, Marie Françoise ^c   Gandemer, Virginie ^d   Bordigoni, Pierre ^e   Lamagnere, Jean Pierre ^f   Demeocq, François ^g   Perel, Yves ^h   Berthou, Christian ⁱ   Bauduer, François ^j   Pautard, Brigitte ^k   Vannier, Jean Pierre ^l   Braguer, Diane ^a   Leblanc, Thierry ^c   Leverger, Guy ^b   Baruchel, André ^c   Michel, Gérard ^a,m  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f UNIVERSITY HOSPITAL OF TOURS   (France)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁱ BREST UNIVERSITY HOSPITAL   (France)

^j Centre Hospitalier de Bayonne   (France)

^k AMIENS UNIVERSITY HOSPITAL   (France)

^l ROUEN UNIVERSITY HOSPITAL   (France)

^m TIMONE HOSPITAL   (France)

more..

Author keywords

Economic costs; Granulocyte colony stimulating factor; Lymphoblastic leukemia; Pediatric leukemia

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; ERYTHROCYTE TRANSFUSION; FEVER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE TRANSFUSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; ECONOMICS, PHARMACEUTICAL; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; NEUTROPENIA; PALLIATIVE CARE; RISK FACTORS; TREATMENT OUTCOME;

EID: 0038724262     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200306000-00004     Document Type: Article

References (19)

1. Chessels JM, Swansbury GJ, Reeves B, et al. Cytogenics and prognosis in childhood lymphoblastic leukaemia: Results of MRC UKALL X-Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 1997;99:93-100.
2. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia. A review. Cancer 1997;80:1717-1726.
3. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1997;338:1663-1671.
4. Steinherz PG, Gaynon P, Miller DR, et al. improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen: A new intensive therapy protocol: A report from the Children's Cancer Study Group. J Clin Oncol 1986;4:744-752.
5. Gaynon PS, Steinherz PG, Bleyer WA, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Children's Cancer Group Study CCG-106. J Clin Oncol 1993;12:2234-2242.
6. Rivera GK, Pinkel D, Simone JV, et al. Treatment of acute lymphoblastic leukemia: A 30 year's experience at St. Jude Children's Research Hospital. N Engl J Med 1993;329:1289-1295.
7. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of multicenter trial ALL-BFM 86. Blood 1994;84:3122-3133.
8. Welte K, Reiter A, Mempel K, et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood 1996;87:3143-3150.
9. Schorin MA, Blattner S, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994;12:740-747.
10. Chessels JM, Bailey C, Richards SM. Intensification of treatment and survival in ALL children with lymphoblastic leukemia: Results of the UK Medical Research Council trial UKALL X. Lancet 1995;345:143-148.
11. Laver J, Amylon M, Desai S, et al. Randomized trial of r-metHu granulocyte colony stimulating factor in an intensive treatment of T-cell leukemia and advanced-stage lymphoblastic lymphoma in childhood: A Pediatric Oncology Group study. J Clin Oncol 1998;16:522-526.
12. American Society of Clinical Oncology. 2000 Update of recommendation for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558-3585.
13. Michel G, Landman-Parker J, Auclerc MF, et al. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: A randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18:1517-1524.
14. Le Corroller AG, Moatti JP. The economic evaluation of hematopoietic growth factors in high-dose chemotherapy. Anticancer Drugs 1998;9:917-924.
15. Gupta P. Granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia [letter]. N Engl J Med 1997;337:1320.
16. Rubino C, Laplanche A, Patte C, et al. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma. J Natl Cancer Inst 1998;90:750-755.
17. Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997;336:1781-1787.
18. Bennet CL, Stinson TJ, Lane D, et al. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: A case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol 2000;34:92-96.
19. Bennett CL, Stinson TJ, Laver JH, et al. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk Lymphoma 2000;37:65-70.